PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
-9.38%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$378M
AUM Growth
+$378M
(+8%)
Cap. Flow
+$77.5M
Cap. Flow
% of AUM
20.49%
Top 10 Holdings %
Top 10 Hldgs %
65.17%
Holding
31
New
7
Increased
16
Reduced
2
Closed
6
Top Buys
| 1 |
Incyte
INCY
|
$18.6M |
| 2 |
Legend Biotech
LEGN
|
$16.2M |
| 3 |
Arvinas
ARVN
|
$15M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$14.3M |
| 5 |
United Therapeutics
UTHR
|
$13.6M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$23.4M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$15.6M |
| 3 |
argenx
ARGX
|
$14.7M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$13.3M |
| 5 |
Insmed
INSM
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $37.7M | 9.98% | 321,621 +103,463 | +47% | +$12.1M |
|
|
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $33.5M | 8.86% | 966,827 +186,347 | +24% | +$6.46M |
|
|
3
Arvinas
ARVN
$568M
| $33.1M | 8.74% | 491,333 +222,814 | +83% | +$15M |
|
|
4
Legend Biotech
LEGN
$6.41B
| $30.2M | 7.99% | 831,728 +445,761 | +115% | +$16.2M |
|
|
SRRA
5
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $24.7M | 6.54% | 771,314 +296,369 | +62% | +$9.5M |
|
6
Viridian Therapeutics
VRDN
$1.5B
| $23.2M | 6.14% | 1,256,051 +47,000 | +4% | +$869K |
|
|
7
Incyte
INCY
$16.5B
| $18.6M | 4.92% | +234,419 | New | +$18.6M |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $15.3M | 4.05% | 910,416 +94,835 | +12% | +$1.6M |
|
9
Iovance Biotherapeutics
IOVA
$807M
| $15.1M | 4% | 907,428 +63,423 | +8% | +$1.06M |
|
10
Immunocore
IMCR
$1.62B
| $14.9M | 3.95% | 499,190 +364,941 | +272% | +$10.9M |
|
|
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.3M | 3.79% | +136,243 | New | +$14.3M |
|
|
12
United Therapeutics
UTHR
$13.8B
| $13.6M | 3.59% | +75,635 | New | +$13.6M |
|
13
Zentalis Pharmaceuticals
ZNTL
$122M
| $13.3M | 3.51% | 287,577 -12,857 | -4% | -$593K |
|
14
Syndax Pharmaceuticals
SNDX
$1.41B
| $12.2M | 3.22% | 701,356 +248,265 | +55% | +$4.31M |
|
15
C4 Therapeutics
CCCC
$185M
| $12.1M | 3.2% | 499,496 +240,750 | +93% | +$5.84M |
|
|
OYST
16
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $11.5M | 3.04% | 987,698 +683,460 | +225% | +$7.96M |
|
17
Prothena Corp
PRTA
$441M
| $9.8M | 2.59% | +267,946 | New | +$9.8M |
|
18
Kymera Therapeutics
KYMR
$2.95B
| $9.61M | 2.54% | 227,034 +101,176 | +80% | +$4.28M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.09M | 2.14% | 98,383 -161,732 | -62% | -$13.3M |
|
20
Merus
MRUS
$4.98B
| $6.6M | 1.75% | +249,738 | New | +$6.6M |
|
21
Vor Biopharma
VOR
$250M
| $5.4M | 1.43% | 894,404 +265,062 | +42% | +$1.6M |
|
22
Esperion Therapeutics
ESPR
$448M
| $5.37M | 1.42% | 1,157,246 +317,989 | +38% | +$1.48M |
|
23
Fulcrum Therapeutics
FULC
$351M
| $5.04M | 1.33% | +212,961 | New | +$5.04M |
|
|
ALPN
24
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $3.02M | 0.8% | +336,229 | New | +$3.02M |
|
|
GRCL
25
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $1.83M | 0.48% | 783,445 +238,057 | +44% | +$555K |
|